Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK2 | O96017 | 1/20 | 0.46 |
| ▸ | PIK3CD | O00329 | 15/20 | 0.45 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.44 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.42 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.42 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.42 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.40 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4007252 | 0.89 | PDE4B (0.47) | CHEK2PIK3CDPDE4B | |
| SCHEMBL4008769 | 0.85 | ROCK1 (0.56) | CHEK2PIK3CDPDE4BPIK3CAPIK3CB | |
| SCHEMBL4476474 | 0.80 | PDE4B (0.53) | CHEK2PIK3CDPDE4BPIK3CAPIK3CB | |
| SCHEMBL4966723 | 0.78 | ROCK1 (0.44) | ROCK1ROCK2KCNH2 | |
| SCHEMBL21999105 | 0.77 | CHEK2 (0.53) | CHEK2PIK3CDPDE4BPIK3CAPIK3CB | |
| SCHEMBL4005950 | 0.76 | CHEK2 (0.51) | CHEK2PIK3CDPDE4BPIK3CAPIK3CB | |
| SCHEMBL20281697 | 0.76 | CHEK2 (0.51) | CHEK2PIK3CDPDE4BPIK3CAPIK3CB | |
| SCHEMBL4002580 | 0.75 | BTK (0.46) | — | |
| SCHEMBL16763551 | 0.75 | PIK3CD (0.51) | CHEK2PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL16763550 | 0.75 | PIK3CD (0.51) | CHEK2PIK3CDPIK3CAPIK3CBPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1963304-B2 | ISOQUINOLINE DERIVATIVES | MSD OSS BV (NL) | 2015-05-13 | — | — | EP | disclosed |
| US-7618985-B2 | Isoquinoline derivatives | N.V. ORGANON (NL) | 2009-11-17 | — | — | US | disclosed |
| EP-1963304-B1 | ISOQUINOLINE DERIVATIVES | ORGANON NV (NL) | 2009-06-24 | — | — | EP | disclosed |
| EP-1963304-A1 | ISOQUINOLINE DERIVATIVES | N.V. Organon (NL) | 2008-09-03 | — | — | EP | disclosed |
| WO-2007065916-A1 | ISOQUINOLINE DERIVATIVES | N.V. ORGANON (NL) | 2007-06-14 | — | — | WO | disclosed |
| US-20070135479-A1 | Isoquinoline derivatives | N.V. ORGANON (NL) | 2007-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135479-A1 | Isoquinoline derivatives | ROCK1, ROCK2, RHOA | CHEK2 2515/4885PIK3CD 527/4885PDE4B 646/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.